ArticleSisli Etfal Hastanesi tip bulteni2022
Frequency of Metabolic Syndrome in Paget's Disease of Bone.
Article in Sisli Etfal Hastanesi tip bulteni, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 3 citations in OpenAlex.
- Paget's Disease of Bone and Chronic Kidney Disease: A Review.Journal of clinical medicine · 2026Review
- Temporal trends of all-cause mortality in Paget's disease of bone: a population-based retrospective cohort study over 20 yr.JBMR plus · 2025Article
- Paget's Disease of the Bone and Lynch Syndrome: An Exceptional Finding.Diagnostics (Basel, Switzerland) · 2023Article
- Alkaline phosphatase and acid phosphatase in health and disease - A systematic review.Journal of oral and maxillofacial pathology : JOMFPReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Our aim is to verify the prevalence of metabolic syndrome (MetS) in Paget's disease of bone (PDB) and to reveal the relationship between MetS and bone alkaline phosphatase (ALP) levels. Methods: Twenty-three patients with PDB and 30 healthy subjects matched with age, sex, and body mass index (BMI) were recruited from the outpatient clinics of endocrinology. The ınternational diabetes federation -2006 MetS criteria were used for the evaluation of all participants. PDB group and control group were compared in terms of MetS and metabolic components of MetS and bone mineral metabolism parameters. Results: When the two groups were compared in terms of weight, waist circumference, BMI, and systolic blood pressure (p=0.09, p=0.644, p=0.78, and p=0.058, respectively), no statistically significant difference was found. The frequency of impaired fasting glucose (IFG) and diabetes mellitus (DM) was determined as 30% (7/23) in the PDB group. There were no patients in the control group with IFG and DM diagnosis. The frequency of IFG and DM was statistically higher in the PDB group than controls (p=0.002). The frequency of MetS was statistically higher in the PDB group than the controls. (73.91%, (17/23) vs.30% (9/30); p<0.01). There was a correlation between ALP level and hypertension medication (p=0.0045, r=0.27). Conclusion: Patients with PDB seem to have MetS more frequently, these patients also should be monitored for MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.